Skip to main content
Joshua Reuss, MD, Oncology, Washington, DC

Joshua Eric Reuss MD


Physician

Join to View Full Profile
  • 3800 Reservoir RdWashington, DC 20007

  • Phone+1 202-444-2223

Dr. Reuss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Internal Medicine, 2014 - 2017
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 2014

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2017 - 2027
  • DC State Medical License
    DC State Medical License 2020 - 2026
  • VA State Medical License
    VA State Medical License 2014 - 2017
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management  
    Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer

Lectures

  • Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Mesothelioma Blood Test, Pre-Surgery Immunotherapy Offer Hope
    Mesothelioma Blood Test, Pre-Surgery Immunotherapy Offer HopeSeptember 16th, 2025
  • First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma
    First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable MesotheliomaSeptember 8th, 2025
  • Research Advances Mesothelioma Insights, Treatment Hopes
    Research Advances Mesothelioma Insights, Treatment HopesSeptember 8th, 2025
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: